Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.97 USD
Change Today +0.07 / 7.78%
Volume 1.7M
OCLS On Other Exchanges
OCLS is not on other exchanges.
As of 4:30 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - $3.48
52 Week Low
05/1/15 - $0.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oculus innovative sciences i (OCLS) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (OCLS) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of organisms that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received eight 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

31 Employees
Last Reported Date: 01/20/15
Founded in 1999

oculus innovative sciences i (OCLS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $263.5K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $250.0K
Executive Vice President of International Ope...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 02:00 PM

Oculus Innovative Sciences, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 02:00 PM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States.

Oculus Innovative Sciences Announces Launch of MicrocynAH(R) Farm and Ranch Animal Healthcare Products

Oculus Innovative Sciences, Inc. announced the introduction of two new MicrocynAH® Farm and Ranch animal healthcare products. Intended for care of traumatic wounds, cuts abrasions, skin irritations, skin ulcers, post-surgical incisions, burns, scratches, rashes and irritated skin, both the MicrocynAH® Farm and Ranch Spray and the MicrocynAH® Farm and Ranch Hydrogel are manufactured with the original patented Microcyn® Technology.

Oculus Innovative Sciences, Inc. Receives Non-Compliance Notice From NASDAQ

On March 6, 2015, Oculus Innovative Sciences, Inc. received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC, notifying the company that, for the last 30 consecutive business days, the company failed to comply with NASDAQ Listing Rule 5550(a)(2), which requires to maintain a minimum bid price of $1.00 per share for common stock. In accordance with Listing Rule 5810(c)(3)(A), NASDAQ granted the company a compliance period of 180 calendar days, or until September 2, 2015, to regain compliance with the Listing Rule. If at any time during this 180 day period the closing bid price of the common stock is at least $1 for a minimum of 10 consecutive business days, the company will regain compliance with the Listing Rule and NASDAQ will close the matter. The letter has no effect on the listing or trading of the common stock at this time. However, there can be no assurance that the company will be able to regain compliance with Listing Rule 5550(a)(2). The company intends to cure the bid price compliance deficiency by effecting a reverse stock split, if necessary.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $0.97 USD +0.07

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,834 JPY +26.50
Henry Schein Inc $142.13 USD -0.85
Integra LifeSciences Holdings Corp $68.07 USD +0.49
Patterson Cos Inc $47.74 USD -0.23
Smith & Nephew PLC 1,155 GBp -6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OCLS Industry Range
Price/Earnings 10.2x
Price/Sales 0.6x
Price/Book 1.0x
Price/Cash Flow 18.4x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at